<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637702</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-543-103</org_study_id>
    <nct_id>NCT00637702</nct_id>
  </id_info>
  <brief_title>A Study of ARRY-334543 in Patients With Advanced Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array Biopharma, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <brief_summary>
    <textblock>
      This is a Phase 1 study during which patients with advanced solid tumors will receive a new&#xD;
      formulation of investigational study drug ARRY-334543. Patients will receive increasing doses&#xD;
      of study drug in order to achieve the highest dose possible that will not cause unacceptable&#xD;
      side effects. The patients will be followed to see what side effects and effectiveness the&#xD;
      study drug has, if any, in treating the cancer. In addition, the effect of food on the new&#xD;
      formulation will be evaluated. Approximately 24 patients from Canada will be enrolled in this&#xD;
      study (Active, not recruiting).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the safety profile of the new formulation of study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish the maximum tolerated dose (MTD) of the new formulation of study drug.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the pharmacokinetics (PK) of the new formulation of study drug (in terms of plasma concentrations) when administered in a fed versus fasted state.</measure>
    <time_frame>Day 1 and Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the exposure of the new formulation of study drug in terms of plasma concentrations.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the efficacy of the new formulation of study drug in terms of tumor dimension assessment.</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>ARRY-334543</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-334543, EGFR/ErbB2 inhibitor; oral</intervention_name>
    <description>single dose and multiple dose, escalating</description>
    <arm_group_label>ARRY-334543</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological evidence of malignancy.&#xD;
&#xD;
          -  Patients with advanced solid tumors who are no longer candidates for standard therapy,&#xD;
             have no standard therapy available, or choose not to pursue standard therapy.&#xD;
&#xD;
          -  Cardiac ejection fraction â‰¥ 50% by echocardiogram (ECHO) or multiple gated acquisition&#xD;
             (MUGA).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled brain metastases (if a patient has brain metastases and is on steroids,&#xD;
             the steroid dose must be stable for at least 30 days).&#xD;
&#xD;
          -  Use of an investigational medication or device within 30 days prior to first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Major surgery within 30 days prior to first dose of study drug.&#xD;
&#xD;
          -  Radiotherapy or chemotherapy within 28 days prior to first dose of study drug (not&#xD;
             including palliative radiotherapy at focal sites).&#xD;
&#xD;
          -  Active, uncontrolled infection requiring systemic antibiotic therapy or other serious&#xD;
             underlying medical condition which would impair the ability of the patient to receive&#xD;
             protocol treatment.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Known positive serology for the human immunodeficiency virus (HIV), 'active' hepatitis&#xD;
             B and/or hepatitis C.&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juravinski Cancer Center at Hamilton Heath Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>October 4, 2020</last_update_submitted>
  <last_update_submitted_qc>October 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

